Rafael Holdings, Inc.

As of June 13, 2023, Rafael Holdings, Inc. is considered overvalued with a valuation grade of "does not qualify," reflected in its low P/E ratio of 4, negative EV to EBITDA of -3.54, and a significant decline in stock performance, indicating deteriorating investment appeal compared to peers.

As of June 18, 2025, the market trend is mildly bearish, indicated by daily moving averages and bearish signals from Bollinger Bands and KST, despite a mildly bullish weekly MACD.

As of March 2022, the management team of Rafael Holdings, Inc. includes Howard Jonas as Chairman and CEO, Stephen Greenberg as Lead Independent Director, and Boris Pasche and Michael Weiss as Independent Directors.

Rafael Holdings, Inc. is a clinical-stage oncology pharmaceutical company focused on developing cancer therapies and also operates in the realty industry, with a market capitalization of approximately $98.92 million. As of January 2025, it reported net sales of $0 million and a net loss of $5 million.

As of Jun 18, Rafael Holdings, Inc. has a market capitalization of 98.92 million, with net sales of 0.72 million and a net loss of 81.68 million over the last four quarters. As of Jul 24, the company reported shareholder's funds of 82.19 million and total assets of 96.83 million.